jang-in-jin

Jang In-Jin
Jang In-Jin

서울대학교의과대학 학사
서울대학교의과대학 대학원 약리학 석사
서울대학교의과대학 대학원 약리학 박사

1991-1994  충북대학교 의과대학 전임강사, 조교수
1994-2001  서울대학교의과대학 전임강사, 조교수
2001–2006  서울대학교의과대학 부교수
2006–          현재 서울대학교의과대학 교수

1998-2000  미국 조지타운 대학교 Center for Drug Development Science, 전임의
2002–2007  서울대학교병원 임상약리실장
2008–2010  서울대학교의과대학  연구부학장
2006– 2017 서울대학교병원 임상시험센터 연구지원실장

2007–           서울대학교병원 임상약리학과장
2012 –          현재 서울대학교 의과대학 약리학교실 주임교수
2017 –          현재  서울대학교병원 임상시험센터 센터장

 

♦ 학회, 위원회 활동

  • 대한임상약리학회 총무이사
  • 대한약리학회 평위원
  • 미국임상약리학회
  • 심사평가원 비상근 위원 (2011)

 

♦ Educational Background

Seoul National University College of Medicine, Seoul, Korea : M.D.
Seoul National University Graduate School, Seoul, Korea : Ph.D.

 

♦ Professional Background

1991-1994  Department of Pharmacology, Chungbuk National Univ. College of Medicine / Lecturer, Assistant Professor
1994-2001  SNU College of Medicine / Lecturer, Assistant Professor
2001–2006  SNU College of Medicine / Associate  Professor
2006–           SNU College of Medicine / Professor

1998-2000  Center for Drug Development Science, Georgetown University Medical Center, Washington DC  / Research Fellow
2002–2007  Dept. of Clinical Pharmacology & Therapeutics, Seoul National University /  Director
2008–2010  Seoul National University College of Medicine  / Associate Dean of Research Affairs
2006– 2017 Clinical Trials Center, Seoul National University Hospital / Director

2007–           Dept. of Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine / Director
2012 –          Dept. of Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine / Professor
2017 –          Clinical Trials Center, Seoul National University Hospital / Director

 

Dr. Jang is a clinical pharmacologist interested in pharmacogenetics, pharmacokinetic/ pharmacodynamic (PK/PD) modeling, population PK, simulation of clinical trial and early clinical drug development methodologies. At Seoul National University Hospital, he is in charge of therapeutic drug monitoring consultation and execution of phase 1 clinical trials. His main research topics are application of imaging, genomic and metabolomic biomarkers to the optimal drug therapy and clinical development of new drugs. He is applying PK/PD modeling and simulation tools to explain the variabilities in drug response with the biomarkers.

 

Back